CMXTwenty Overview

Oral CMX-020, a new molecular entity, is being developed as a first-in-class, non-opioid analgesic for both acute and chronic pain administered alone or in combination with other therapeutics. We have developed both intravenous and oral drug candidates with safety and efficacy profiles powerful enough to replace opioids as the standard of care for severe pain relief.

Contact Information

Address: PO Box 26906, Wauwatosa, WI 53226-0906